nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxylamine—Cardiac disorder—Vemurafenib—skin cancer	0.00679	0.00679	CcSEcCtD
Doxylamine—Mediastinal disorder—Vemurafenib—skin cancer	0.0066	0.0066	CcSEcCtD
Doxylamine—Erythema—Vemurafenib—skin cancer	0.00637	0.00637	CcSEcCtD
Doxylamine—Urinary tract disorder—Imiquimod—skin cancer	0.00617	0.00617	CcSEcCtD
Doxylamine—Urethral disorder—Imiquimod—skin cancer	0.00612	0.00612	CcSEcCtD
Doxylamine—Rhinorrhoea—Docetaxel—skin cancer	0.00612	0.00612	CcSEcCtD
Doxylamine—Asthenia—Vismodegib—skin cancer	0.00604	0.00604	CcSEcCtD
Doxylamine—Pruritus—Vismodegib—skin cancer	0.00596	0.00596	CcSEcCtD
Doxylamine—Erythema multiforme—Imiquimod—skin cancer	0.0059	0.0059	CcSEcCtD
Doxylamine—Eye disorder—Imiquimod—skin cancer	0.00584	0.00584	CcSEcCtD
Doxylamine—Flushing—Imiquimod—skin cancer	0.00579	0.00579	CcSEcCtD
Doxylamine—Diarrhoea—Vismodegib—skin cancer	0.00576	0.00576	CcSEcCtD
Doxylamine—Immune system disorder—Imiquimod—skin cancer	0.00564	0.00564	CcSEcCtD
Doxylamine—Mediastinal disorder—Imiquimod—skin cancer	0.00563	0.00563	CcSEcCtD
Doxylamine—Bone disorder—Docetaxel—skin cancer	0.00549	0.00549	CcSEcCtD
Doxylamine—Bronchospasm—Bleomycin—skin cancer	0.00545	0.00545	CcSEcCtD
Doxylamine—Erythema—Imiquimod—skin cancer	0.00544	0.00544	CcSEcCtD
Doxylamine—Diplopia—Temozolomide—skin cancer	0.00541	0.00541	CcSEcCtD
Doxylamine—Toxic epidermal necrolysis—Dactinomycin—skin cancer	0.00538	0.00538	CcSEcCtD
Doxylamine—Lacrimation increased—Docetaxel—skin cancer	0.00538	0.00538	CcSEcCtD
Doxylamine—Vomiting—Vismodegib—skin cancer	0.00535	0.00535	CcSEcCtD
Doxylamine—Affect lability—Temozolomide—skin cancer	0.00532	0.00532	CcSEcCtD
Doxylamine—Rash—Vismodegib—skin cancer	0.00531	0.00531	CcSEcCtD
Doxylamine—Dermatitis—Vismodegib—skin cancer	0.0053	0.0053	CcSEcCtD
Doxylamine—Pancytopenia—Bleomycin—skin cancer	0.00526	0.00526	CcSEcCtD
Doxylamine—Anaphylactic shock—Vemurafenib—skin cancer	0.0052	0.0052	CcSEcCtD
Doxylamine—Mood swings—Temozolomide—skin cancer	0.00512	0.00512	CcSEcCtD
Doxylamine—Nervous system disorder—Vemurafenib—skin cancer	0.0051	0.0051	CcSEcCtD
Doxylamine—Ill-defined disorder—Imiquimod—skin cancer	0.00504	0.00504	CcSEcCtD
Doxylamine—Dehydration—Temozolomide—skin cancer	0.00503	0.00503	CcSEcCtD
Doxylamine—Nausea—Vismodegib—skin cancer	0.005	0.005	CcSEcCtD
Doxylamine—Agitation—Imiquimod—skin cancer	0.00499	0.00499	CcSEcCtD
Doxylamine—Angioedema—Imiquimod—skin cancer	0.00497	0.00497	CcSEcCtD
Doxylamine—Pancytopenia—Dactinomycin—skin cancer	0.00491	0.00491	CcSEcCtD
Doxylamine—Malaise—Imiquimod—skin cancer	0.0049	0.0049	CcSEcCtD
Doxylamine—Breast disorder—Temozolomide—skin cancer	0.00489	0.00489	CcSEcCtD
Doxylamine—Toxic epidermal necrolysis—Temozolomide—skin cancer	0.00487	0.00487	CcSEcCtD
Doxylamine—Hypotension—Vemurafenib—skin cancer	0.00486	0.00486	CcSEcCtD
Doxylamine—Palpitations—Imiquimod—skin cancer	0.0048	0.0048	CcSEcCtD
Doxylamine—Irritability—Fluorouracil—skin cancer	0.00476	0.00476	CcSEcCtD
Doxylamine—Convulsion—Imiquimod—skin cancer	0.00471	0.00471	CcSEcCtD
Doxylamine—Anxiety—Imiquimod—skin cancer	0.00461	0.00461	CcSEcCtD
Doxylamine—Discomfort—Imiquimod—skin cancer	0.00457	0.00457	CcSEcCtD
Doxylamine—Stevens-Johnson syndrome—Dactinomycin—skin cancer	0.00457	0.00457	CcSEcCtD
Doxylamine—Sweating increased—Temozolomide—skin cancer	0.00455	0.00455	CcSEcCtD
Doxylamine—Dry mouth—Imiquimod—skin cancer	0.00453	0.00453	CcSEcCtD
Doxylamine—Decreased appetite—Vemurafenib—skin cancer	0.00452	0.00452	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Vemurafenib—skin cancer	0.00449	0.00449	CcSEcCtD
Doxylamine—Fatigue—Vemurafenib—skin cancer	0.00448	0.00448	CcSEcCtD
Doxylamine—Nasopharyngitis—Fluorouracil—skin cancer	0.00446	0.00446	CcSEcCtD
Doxylamine—Constipation—Vemurafenib—skin cancer	0.00445	0.00445	CcSEcCtD
Doxylamine—Pancytopenia—Temozolomide—skin cancer	0.00444	0.00444	CcSEcCtD
Doxylamine—Nervous system disorder—Imiquimod—skin cancer	0.00435	0.00435	CcSEcCtD
Doxylamine—Tachycardia—Imiquimod—skin cancer	0.00433	0.00433	CcSEcCtD
Doxylamine—Agranulocytosis—Dactinomycin—skin cancer	0.0043	0.0043	CcSEcCtD
Doxylamine—Hyperhidrosis—Imiquimod—skin cancer	0.00429	0.00429	CcSEcCtD
Doxylamine—Anorexia—Imiquimod—skin cancer	0.00423	0.00423	CcSEcCtD
Doxylamine—Depression—Temozolomide—skin cancer	0.00416	0.00416	CcSEcCtD
Doxylamine—Hepatitis—Dactinomycin—skin cancer	0.00414	0.00414	CcSEcCtD
Doxylamine—Stevens-Johnson syndrome—Temozolomide—skin cancer	0.00413	0.00413	CcSEcCtD
Doxylamine—Flushing—Bleomycin—skin cancer	0.00412	0.00412	CcSEcCtD
Doxylamine—Pancytopenia—Fluorouracil—skin cancer	0.00409	0.00409	CcSEcCtD
Doxylamine—Insomnia—Imiquimod—skin cancer	0.00401	0.00401	CcSEcCtD
Doxylamine—Dyspnoea—Imiquimod—skin cancer	0.00395	0.00395	CcSEcCtD
Doxylamine—Somnolence—Imiquimod—skin cancer	0.00394	0.00394	CcSEcCtD
Doxylamine—Erythema multiforme—Dactinomycin—skin cancer	0.00391	0.00391	CcSEcCtD
Doxylamine—Erythema—Bleomycin—skin cancer	0.00386	0.00386	CcSEcCtD
Doxylamine—Decreased appetite—Imiquimod—skin cancer	0.00386	0.00386	CcSEcCtD
Doxylamine—Flushing—Dactinomycin—skin cancer	0.00384	0.00384	CcSEcCtD
Doxylamine—Hypersensitivity—Vemurafenib—skin cancer	0.00383	0.00383	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Imiquimod—skin cancer	0.00383	0.00383	CcSEcCtD
Doxylamine—Fatigue—Imiquimod—skin cancer	0.00382	0.00382	CcSEcCtD
Doxylamine—Hepatitis—Temozolomide—skin cancer	0.00374	0.00374	CcSEcCtD
Doxylamine—Asthenia—Vemurafenib—skin cancer	0.00373	0.00373	CcSEcCtD
Doxylamine—Hallucination—Temozolomide—skin cancer	0.00372	0.00372	CcSEcCtD
Doxylamine—Urinary tract disorder—Temozolomide—skin cancer	0.0037	0.0037	CcSEcCtD
Doxylamine—Pruritus—Vemurafenib—skin cancer	0.00368	0.00368	CcSEcCtD
Doxylamine—Urethral disorder—Temozolomide—skin cancer	0.00367	0.00367	CcSEcCtD
Doxylamine—Feeling abnormal—Imiquimod—skin cancer	0.00366	0.00366	CcSEcCtD
Doxylamine—Erythema—Dactinomycin—skin cancer	0.0036	0.0036	CcSEcCtD
Doxylamine—Agranulocytosis—Fluorouracil—skin cancer	0.00358	0.00358	CcSEcCtD
Doxylamine—Ill-defined disorder—Bleomycin—skin cancer	0.00358	0.00358	CcSEcCtD
Doxylamine—Diarrhoea—Vemurafenib—skin cancer	0.00356	0.00356	CcSEcCtD
Doxylamine—Erythema multiforme—Temozolomide—skin cancer	0.00354	0.00354	CcSEcCtD
Doxylamine—Urticaria—Imiquimod—skin cancer	0.00352	0.00352	CcSEcCtD
Doxylamine—Eye disorder—Temozolomide—skin cancer	0.0035	0.0035	CcSEcCtD
Doxylamine—Malaise—Bleomycin—skin cancer	0.00348	0.00348	CcSEcCtD
Doxylamine—Flushing—Temozolomide—skin cancer	0.00347	0.00347	CcSEcCtD
Doxylamine—Cardiac disorder—Temozolomide—skin cancer	0.00347	0.00347	CcSEcCtD
Doxylamine—Leukopenia—Bleomycin—skin cancer	0.00346	0.00346	CcSEcCtD
Doxylamine—Dizziness—Vemurafenib—skin cancer	0.00344	0.00344	CcSEcCtD
Doxylamine—Immune system disorder—Temozolomide—skin cancer	0.00338	0.00338	CcSEcCtD
Doxylamine—Mediastinal disorder—Temozolomide—skin cancer	0.00337	0.00337	CcSEcCtD
Doxylamine—Dehydration—Docetaxel—skin cancer	0.00335	0.00335	CcSEcCtD
Doxylamine—Ill-defined disorder—Dactinomycin—skin cancer	0.00334	0.00334	CcSEcCtD
Doxylamine—Vomiting—Vemurafenib—skin cancer	0.00331	0.00331	CcSEcCtD
Doxylamine—Orthostatic hypotension—Docetaxel—skin cancer	0.00329	0.00329	CcSEcCtD
Doxylamine—Rash—Vemurafenib—skin cancer	0.00328	0.00328	CcSEcCtD
Doxylamine—Dermatitis—Vemurafenib—skin cancer	0.00328	0.00328	CcSEcCtD
Doxylamine—Hypersensitivity—Imiquimod—skin cancer	0.00327	0.00327	CcSEcCtD
Doxylamine—Erythema—Temozolomide—skin cancer	0.00326	0.00326	CcSEcCtD
Doxylamine—Breast disorder—Docetaxel—skin cancer	0.00325	0.00325	CcSEcCtD
Doxylamine—Discomfort—Bleomycin—skin cancer	0.00325	0.00325	CcSEcCtD
Doxylamine—Malaise—Dactinomycin—skin cancer	0.00325	0.00325	CcSEcCtD
Doxylamine—Toxic epidermal necrolysis—Docetaxel—skin cancer	0.00324	0.00324	CcSEcCtD
Doxylamine—Cramp muscle—Docetaxel—skin cancer	0.00324	0.00324	CcSEcCtD
Doxylamine—Leukopenia—Dactinomycin—skin cancer	0.00322	0.00322	CcSEcCtD
Doxylamine—Nasopharyngitis—Docetaxel—skin cancer	0.00322	0.00322	CcSEcCtD
Doxylamine—Asthenia—Imiquimod—skin cancer	0.00318	0.00318	CcSEcCtD
Doxylamine—Confusional state—Bleomycin—skin cancer	0.00318	0.00318	CcSEcCtD
Doxylamine—Anaphylactic shock—Bleomycin—skin cancer	0.00315	0.00315	CcSEcCtD
Doxylamine—Pruritus—Imiquimod—skin cancer	0.00314	0.00314	CcSEcCtD
Doxylamine—Nausea—Vemurafenib—skin cancer	0.00309	0.00309	CcSEcCtD
Doxylamine—Thrombocytopenia—Bleomycin—skin cancer	0.00309	0.00309	CcSEcCtD
Doxylamine—Bronchospasm—Docetaxel—skin cancer	0.00306	0.00306	CcSEcCtD
Doxylamine—Tremor—Temozolomide—skin cancer	0.00305	0.00305	CcSEcCtD
Doxylamine—Diarrhoea—Imiquimod—skin cancer	0.00304	0.00304	CcSEcCtD
Doxylamine—Discomfort—Dactinomycin—skin cancer	0.00303	0.00303	CcSEcCtD
Doxylamine—Ill-defined disorder—Temozolomide—skin cancer	0.00302	0.00302	CcSEcCtD
Doxylamine—Anorexia—Bleomycin—skin cancer	0.003	0.003	CcSEcCtD
Doxylamine—Erythema—Fluorouracil—skin cancer	0.003	0.003	CcSEcCtD
Doxylamine—Agitation—Temozolomide—skin cancer	0.00299	0.00299	CcSEcCtD
Doxylamine—Angioedema—Temozolomide—skin cancer	0.00298	0.00298	CcSEcCtD
Doxylamine—Pancytopenia—Docetaxel—skin cancer	0.00295	0.00295	CcSEcCtD
Doxylamine—Hypotension—Bleomycin—skin cancer	0.00294	0.00294	CcSEcCtD
Doxylamine—Malaise—Temozolomide—skin cancer	0.00294	0.00294	CcSEcCtD
Doxylamine—Dizziness—Imiquimod—skin cancer	0.00293	0.00293	CcSEcCtD
Doxylamine—Vertigo—Temozolomide—skin cancer	0.00293	0.00293	CcSEcCtD
Doxylamine—Leukopenia—Temozolomide—skin cancer	0.00292	0.00292	CcSEcCtD
Doxylamine—Palpitations—Temozolomide—skin cancer	0.00288	0.00288	CcSEcCtD
Doxylamine—Thrombocytopenia—Dactinomycin—skin cancer	0.00288	0.00288	CcSEcCtD
Doxylamine—Convulsion—Temozolomide—skin cancer	0.00282	0.00282	CcSEcCtD
Doxylamine—Vomiting—Imiquimod—skin cancer	0.00282	0.00282	CcSEcCtD
Doxylamine—Dyspnoea—Bleomycin—skin cancer	0.00281	0.00281	CcSEcCtD
Doxylamine—Anorexia—Dactinomycin—skin cancer	0.0028	0.0028	CcSEcCtD
Doxylamine—Rash—Imiquimod—skin cancer	0.0028	0.0028	CcSEcCtD
Doxylamine—Dermatitis—Imiquimod—skin cancer	0.00279	0.00279	CcSEcCtD
Doxylamine—Anxiety—Temozolomide—skin cancer	0.00276	0.00276	CcSEcCtD
Doxylamine—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.00275	0.00275	CcSEcCtD
Doxylamine—Discomfort—Temozolomide—skin cancer	0.00274	0.00274	CcSEcCtD
Doxylamine—Decreased appetite—Bleomycin—skin cancer	0.00274	0.00274	CcSEcCtD
Doxylamine—Dry mouth—Temozolomide—skin cancer	0.00271	0.00271	CcSEcCtD
Doxylamine—Leukopenia—Fluorouracil—skin cancer	0.00269	0.00269	CcSEcCtD
Doxylamine—Confusional state—Temozolomide—skin cancer	0.00268	0.00268	CcSEcCtD
Doxylamine—Anaphylactic shock—Temozolomide—skin cancer	0.00266	0.00266	CcSEcCtD
Doxylamine—Nausea—Imiquimod—skin cancer	0.00263	0.00263	CcSEcCtD
Doxylamine—Nervous system disorder—Temozolomide—skin cancer	0.00261	0.00261	CcSEcCtD
Doxylamine—Thrombocytopenia—Temozolomide—skin cancer	0.0026	0.0026	CcSEcCtD
Doxylamine—Convulsion—Fluorouracil—skin cancer	0.0026	0.0026	CcSEcCtD
Doxylamine—Feeling abnormal—Bleomycin—skin cancer	0.0026	0.0026	CcSEcCtD
Doxylamine—Agranulocytosis—Docetaxel—skin cancer	0.00259	0.00259	CcSEcCtD
Doxylamine—Hyperhidrosis—Temozolomide—skin cancer	0.00257	0.00257	CcSEcCtD
Doxylamine—Decreased appetite—Dactinomycin—skin cancer	0.00255	0.00255	CcSEcCtD
Doxylamine—Fatigue—Dactinomycin—skin cancer	0.00253	0.00253	CcSEcCtD
Doxylamine—Anorexia—Temozolomide—skin cancer	0.00253	0.00253	CcSEcCtD
Doxylamine—Discomfort—Fluorouracil—skin cancer	0.00252	0.00252	CcSEcCtD
Doxylamine—Urticaria—Bleomycin—skin cancer	0.0025	0.0025	CcSEcCtD
Doxylamine—Hepatitis—Docetaxel—skin cancer	0.00249	0.00249	CcSEcCtD
Doxylamine—Confusional state—Fluorouracil—skin cancer	0.00247	0.00247	CcSEcCtD
Doxylamine—Urinary tract disorder—Docetaxel—skin cancer	0.00246	0.00246	CcSEcCtD
Doxylamine—Anaphylactic shock—Fluorouracil—skin cancer	0.00245	0.00245	CcSEcCtD
Doxylamine—Urethral disorder—Docetaxel—skin cancer	0.00244	0.00244	CcSEcCtD
Doxylamine—Feeling abnormal—Dactinomycin—skin cancer	0.00242	0.00242	CcSEcCtD
Doxylamine—Insomnia—Temozolomide—skin cancer	0.0024	0.0024	CcSEcCtD
Doxylamine—Nervous system disorder—Fluorouracil—skin cancer	0.0024	0.0024	CcSEcCtD
Doxylamine—Thrombocytopenia—Fluorouracil—skin cancer	0.0024	0.0024	CcSEcCtD
Doxylamine—Tachycardia—Fluorouracil—skin cancer	0.00239	0.00239	CcSEcCtD
Doxylamine—Dyspnoea—Temozolomide—skin cancer	0.00237	0.00237	CcSEcCtD
Doxylamine—Somnolence—Temozolomide—skin cancer	0.00236	0.00236	CcSEcCtD
Doxylamine—Erythema multiforme—Docetaxel—skin cancer	0.00235	0.00235	CcSEcCtD
Doxylamine—Anorexia—Fluorouracil—skin cancer	0.00233	0.00233	CcSEcCtD
Doxylamine—Eye disorder—Docetaxel—skin cancer	0.00233	0.00233	CcSEcCtD
Doxylamine—Hypersensitivity—Bleomycin—skin cancer	0.00232	0.00232	CcSEcCtD
Doxylamine—Decreased appetite—Temozolomide—skin cancer	0.00231	0.00231	CcSEcCtD
Doxylamine—Flushing—Docetaxel—skin cancer	0.00231	0.00231	CcSEcCtD
Doxylamine—Cardiac disorder—Docetaxel—skin cancer	0.00231	0.00231	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Temozolomide—skin cancer	0.0023	0.0023	CcSEcCtD
Doxylamine—Fatigue—Temozolomide—skin cancer	0.00229	0.00229	CcSEcCtD
Doxylamine—Hypotension—Fluorouracil—skin cancer	0.00229	0.00229	CcSEcCtD
Doxylamine—Constipation—Temozolomide—skin cancer	0.00227	0.00227	CcSEcCtD
Doxylamine—Asthenia—Bleomycin—skin cancer	0.00226	0.00226	CcSEcCtD
Doxylamine—Immune system disorder—Docetaxel—skin cancer	0.00225	0.00225	CcSEcCtD
Doxylamine—Mediastinal disorder—Docetaxel—skin cancer	0.00224	0.00224	CcSEcCtD
Doxylamine—Pruritus—Bleomycin—skin cancer	0.00223	0.00223	CcSEcCtD
Doxylamine—Insomnia—Fluorouracil—skin cancer	0.00222	0.00222	CcSEcCtD
Doxylamine—Feeling abnormal—Temozolomide—skin cancer	0.00219	0.00219	CcSEcCtD
Doxylamine—Dyspnoea—Fluorouracil—skin cancer	0.00218	0.00218	CcSEcCtD
Doxylamine—Somnolence—Fluorouracil—skin cancer	0.00218	0.00218	CcSEcCtD
Doxylamine—Erythema—Docetaxel—skin cancer	0.00217	0.00217	CcSEcCtD
Doxylamine—Hypersensitivity—Dactinomycin—skin cancer	0.00217	0.00217	CcSEcCtD
Doxylamine—Decreased appetite—Fluorouracil—skin cancer	0.00213	0.00213	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Fluorouracil—skin cancer	0.00211	0.00211	CcSEcCtD
Doxylamine—Urticaria—Temozolomide—skin cancer	0.00211	0.00211	CcSEcCtD
Doxylamine—Asthenia—Dactinomycin—skin cancer	0.00211	0.00211	CcSEcCtD
Doxylamine—Muscle spasms—Docetaxel—skin cancer	0.00208	0.00208	CcSEcCtD
Doxylamine—Feeling abnormal—Fluorouracil—skin cancer	0.00202	0.00202	CcSEcCtD
Doxylamine—Diarrhoea—Dactinomycin—skin cancer	0.00201	0.00201	CcSEcCtD
Doxylamine—Vomiting—Bleomycin—skin cancer	0.002	0.002	CcSEcCtD
Doxylamine—Rash—Bleomycin—skin cancer	0.00199	0.00199	CcSEcCtD
Doxylamine—Dermatitis—Bleomycin—skin cancer	0.00199	0.00199	CcSEcCtD
Doxylamine—Hypersensitivity—Temozolomide—skin cancer	0.00196	0.00196	CcSEcCtD
Doxylamine—Urticaria—Fluorouracil—skin cancer	0.00195	0.00195	CcSEcCtD
Doxylamine—Leukopenia—Docetaxel—skin cancer	0.00194	0.00194	CcSEcCtD
Doxylamine—Palpitations—Docetaxel—skin cancer	0.00191	0.00191	CcSEcCtD
Doxylamine—Asthenia—Temozolomide—skin cancer	0.00191	0.00191	CcSEcCtD
Doxylamine—Pruritus—Temozolomide—skin cancer	0.00188	0.00188	CcSEcCtD
Doxylamine—Convulsion—Docetaxel—skin cancer	0.00188	0.00188	CcSEcCtD
Doxylamine—Nausea—Bleomycin—skin cancer	0.00187	0.00187	CcSEcCtD
Doxylamine—Vomiting—Dactinomycin—skin cancer	0.00187	0.00187	CcSEcCtD
Doxylamine—Rash—Dactinomycin—skin cancer	0.00185	0.00185	CcSEcCtD
Doxylamine—Diarrhoea—Temozolomide—skin cancer	0.00182	0.00182	CcSEcCtD
Doxylamine—Hypersensitivity—Fluorouracil—skin cancer	0.0018	0.0018	CcSEcCtD
Doxylamine—Dry mouth—Docetaxel—skin cancer	0.0018	0.0018	CcSEcCtD
Doxylamine—Confusional state—Docetaxel—skin cancer	0.00178	0.00178	CcSEcCtD
Doxylamine—Anaphylactic shock—Docetaxel—skin cancer	0.00177	0.00177	CcSEcCtD
Doxylamine—Dizziness—Temozolomide—skin cancer	0.00176	0.00176	CcSEcCtD
Doxylamine—Nausea—Dactinomycin—skin cancer	0.00175	0.00175	CcSEcCtD
Doxylamine—Nervous system disorder—Docetaxel—skin cancer	0.00173	0.00173	CcSEcCtD
Doxylamine—Pruritus—Fluorouracil—skin cancer	0.00173	0.00173	CcSEcCtD
Doxylamine—Thrombocytopenia—Docetaxel—skin cancer	0.00173	0.00173	CcSEcCtD
Doxylamine—Tachycardia—Docetaxel—skin cancer	0.00173	0.00173	CcSEcCtD
Doxylamine—Vomiting—Temozolomide—skin cancer	0.00169	0.00169	CcSEcCtD
Doxylamine—Anorexia—Docetaxel—skin cancer	0.00169	0.00169	CcSEcCtD
Doxylamine—Rash—Temozolomide—skin cancer	0.00168	0.00168	CcSEcCtD
Doxylamine—Diarrhoea—Fluorouracil—skin cancer	0.00168	0.00168	CcSEcCtD
Doxylamine—Dermatitis—Temozolomide—skin cancer	0.00167	0.00167	CcSEcCtD
Doxylamine—Hypotension—Docetaxel—skin cancer	0.00165	0.00165	CcSEcCtD
Doxylamine—Dizziness—Fluorouracil—skin cancer	0.00162	0.00162	CcSEcCtD
Doxylamine—Insomnia—Docetaxel—skin cancer	0.0016	0.0016	CcSEcCtD
Doxylamine—Nausea—Temozolomide—skin cancer	0.00158	0.00158	CcSEcCtD
Doxylamine—Dyspnoea—Docetaxel—skin cancer	0.00158	0.00158	CcSEcCtD
Doxylamine—Somnolence—Docetaxel—skin cancer	0.00157	0.00157	CcSEcCtD
Doxylamine—Vomiting—Fluorouracil—skin cancer	0.00156	0.00156	CcSEcCtD
Doxylamine—Rash—Fluorouracil—skin cancer	0.00154	0.00154	CcSEcCtD
Doxylamine—Dermatitis—Fluorouracil—skin cancer	0.00154	0.00154	CcSEcCtD
Doxylamine—Decreased appetite—Docetaxel—skin cancer	0.00154	0.00154	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Docetaxel—skin cancer	0.00153	0.00153	CcSEcCtD
Doxylamine—Fatigue—Docetaxel—skin cancer	0.00152	0.00152	CcSEcCtD
Doxylamine—Constipation—Docetaxel—skin cancer	0.00151	0.00151	CcSEcCtD
Doxylamine—Feeling abnormal—Docetaxel—skin cancer	0.00146	0.00146	CcSEcCtD
Doxylamine—Nausea—Fluorouracil—skin cancer	0.00145	0.00145	CcSEcCtD
Doxylamine—Hypersensitivity—Docetaxel—skin cancer	0.0013	0.0013	CcSEcCtD
Doxylamine—Asthenia—Docetaxel—skin cancer	0.00127	0.00127	CcSEcCtD
Doxylamine—Pruritus—Docetaxel—skin cancer	0.00125	0.00125	CcSEcCtD
Doxylamine—Diarrhoea—Docetaxel—skin cancer	0.00121	0.00121	CcSEcCtD
Doxylamine—Dizziness—Docetaxel—skin cancer	0.00117	0.00117	CcSEcCtD
Doxylamine—Vomiting—Docetaxel—skin cancer	0.00112	0.00112	CcSEcCtD
Doxylamine—Rash—Docetaxel—skin cancer	0.00111	0.00111	CcSEcCtD
Doxylamine—Dermatitis—Docetaxel—skin cancer	0.00111	0.00111	CcSEcCtD
Doxylamine—Nausea—Docetaxel—skin cancer	0.00105	0.00105	CcSEcCtD
